Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

Inclusion Criteria Concurrent Medication: Allowed: * Systemic or oral antibiotics. * Experimental drugs (IND drugs) which are targeted specifically against the AIDS (group IV CDC classification) virus or stimulate the immune system. Patients with the following conditions are included: * AIDS or AIDS related complex (ARC) (HIV infection Group 3 or 4, CDC classification) who have had culture-proven oral candidiasis clinically cured within 7 days of study entry and are likely to be compliant for the 20 weeks of nystatin pastille prophylaxis. * Able to follow instructions regarding the use of a pastille. * Patients entering part II of this study (randomized double-blind) must have been clinically cured of oral candidiasis within 1 - 7 days of entry into this randomized study. * Oral lesions such as Kaposi's sarcoma, herpes zoster, and herpes simplex can be enrolled. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Systemic candidiasis. * Hypersensitivity to nystatin. * Suspected or proven candidal esophagitis. Patients with the following are excluded: * Systemic candidiasis. * Projected survival of less than 6 months. * Unable to maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. * Hypersensitivity to nystatin. * Suspected or proven candidal esophagitis.